Đánh giá tính an toàn và tính sinh miễn dịch của vắc xin Rotavin-M1 do Việt Nam sản xuất

36. Bernstein DI, Sack DA, Rothstein E, et al. (1999), "Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial", Lancet; 354(9175): 287-90.

37. Bernstein DI, Smith VE, Sherwood JR, et al. (1998), "Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12", Vaccine;16(4): 381-7.

38. Bernstein DI. (2000), "Rotavirus vaccine: current status and future prospects". BioDrugs; 14(5):275-81.

39. Bhandari N, Sharma p, Glass RI. (2006), “Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and 1321, in infants: results of a randomised controlled trial”, Vaccine, 24(31-32), pp. 5817-23.

40. Bishop RF, Bames GL, Cipriani E, et al (1983), “Clinical immunity after neonatal Rotavirus infection: a prospective longitudinal study in young children”, NEngl JMed, 309(2), pp. 72-76.

41. Bishop RF, Davidson GP, Holmes IH, et al (1973), "Virus particles in epithelial cells of duodenal mucosa from children with acute non- bacterial gastroenteritis", Lancet, 2(7841), pp. 1281-3.

42. Bishop, R.F., Davidson, G.P., Holmes, I.H. et al (1974), "Detection of a new virus by electron microscopy of faecal extracts from children with acute gastroenteritis", Lancet, pp. 149 - 151. (36)

43. Black RE, Merson HR, Huq I et al (1981), “Incidence and severity of rotavirus and Escherichia coli diarrhoea in rural Bangladesh: Implications for vaccine development”, Lancet, 1, pp. 141.

44. Block SL, Vesikari T, Goveia MG et al (2007), “Efficacy, Immunogenicity and Safety of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf Life”, Pediatrics, 119(1), pp. 11-8.

Có thể bạn quan tâm!

Xem toàn bộ 163 trang tài liệu này.

45. Bodhidatta L, Nguyen Thi Phong Lan, Bui Thu Hien et al (2007), “Rotavirus disease in young children from Hanoi, Vietnam”, The Pediatric Infectious Disease Journal, 26(4), pp. 325-328.

46. Bresee JS, Hummelman E, Nelson EAS, et al (2005), “Rotavirus in Asia: The Value of Surveillance for Informing Decisions about the Introduction of New Vaccines”, J.Infect Dis, 192, pp. S1-S5.

47. Bridger JC., Woode GN. (1976), "Characterization of two particle types of calf Rotavirus", J Gen Virol, 31, pp. 245 - 250.

48. Brown DW, Campbell L, Tomkins DS, et al (1989). "School outbreak of gastroenteritis due to atypical rotavirus", Lancet, 2(8665), pp. 737- 8.

49. Bryce J, Boschi-Pinto c, Shibuya K, Black R. (2005), "WHO estimates of the causes of death in children", Lancet, 365(9465), pp. l 147-1152.

50. Bucardo F, Karlsson B, Nordgren J, et al (2007), "Mutated G4P[8] rotavirus associated with a nationwide outbreak of gastroenteritis in Nicaragua in 2005", J Clin Microbiol, 45(3), pp. 990-7.

51. Bums J.W., Welch S.K., Nkata S., Estes M.K. (1989), “Characterization of monoclonal antibodies to human group B Rotavirus and their use in an antigen detaction enzyme liked immunosorbent assay”, J., Clin., Microbiol, (27), pp. 245-250.

52. Carl Q.-Y Zeng, Mary K Estes, Annie Charpilienne, and Jean Cohen (1998), "The N Terminus of Rotavirus VP2 is Necessary for Encapsidation of VP1 and VP3", Journal of Virology, pp. 201-208.

53. Centers for Disease Control and Prevention (1999), "Withdrawal of rotaviruts vaccine recommendation", Jama, 282: pp.2113-2114.

54. Chalmers TC (1983), “The control of bias in clinical trials”, In: Clinical

Trials (Shaprio SH, Louis TA, eds), Marcel Dekker, New York, pp.115.

55. Chang CC, Chang MH, Lin TY, et al (2009), “Experience of Pentavalent Human-bovine Reassortant Rotavirus Vaccine Among Healthy Infants in Taiwan”, J Formos Med Assoc, 108(4), pp. 280-285.

56. Charles W L., Michelle H., Patricia W. et al (1992), Participatins Laboratories in the National Rotavirus Surveillance System Out break of summer Rotavirus linked to laboratory practices, Paediatr infect Dis, 11, pp. 860 - 864.

57. Charles W. Lebaron, Judy F. Flew, Roger I Glass, et al (1990), "Annual Rotavirus Epidemic Pattern in North America", JAMA, Vol 264, pp. 983 - 987.

58. Ciarlet M, He s, Lai s, et al (2009), “Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B- Inactivated Polio - Haemophilus influenzae Type B vaccine”, Pediatr Infect Dis J, 28(3), pp. 177-81.

59. Ciarlet M, Hyser JM, Estes MK (2002), “Sequence analysis of the VP4, VP6, VP7 and NSP4 gene Products of the bovine rotavirus WC3”, Virus Genes, 24(2), pp. 103-114.

60. Clark H.F., Offit P.A., Ellis R.W. et al. (1996), “The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine forinfant”,

J. Infect Dis., 174 (Suppl.l): S73- S80.

61. Clark H.F., Offit P.A., Ellis R.W., et al. (1996), “WC3 reassortant vaccines in children”, Arch Virol; (Suppl 12): pp. 187-198.

62. Clark HF, Furukawa T, Bell LM, et al (1986), “Immune response of infants and children to low-passage bovine rotavirus (strain WC3)”, Am JDis Child, 140(4), pp. 350-6.

63. Clark HF, Offìt PA, Ellis RW, et al (1996), “The development of multivalent bovine Rotavirus (strain WC3) reassortant vaccine for infants”, J Infect Dis, 174(suppl 1), pp. S73-S80.

64. Clark HF, Offit PA, Glass RI, et al (2004), “Rotavirus vaccines, In: Vaccines, 4th (Plotkin SA, Orenstein WA, eds), Philadelphia, PA. Saunders-Elsevier, USA, pp. 1327-45.

65. Comstock G. (1994), “Evaluating vaccination effectiveness and vaccine efficacy by means of case-control study”, Epidemiol Rev, 16, pp. 77-89.

66. Coulson, B.S., Holmes, I.H. (1984), "An Improved Enzyme-Linked Immunosorbent Assay for the Detection of Rotavirus in Faeces of Neonates", J. Virol Methods, 8, pp. 165 - 179.

67. Dang Duc Anh, Nguyen Van Trang, Vu Dinh Thiem, et al (2012), "A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children", Vaccine 30S, A114-A121.

68. Dang Duc Anh, Vu Dinh Thiem, Thea KF et al (2006), “The Burden of Rotavirus Diarrhea in Khanh Hoa Province, Vietnam: Baseline Assessment for a Rotavirus Vaccine Trial", The Pediatric Infectious Disease Journal, 25(1), pp. 37 - 40.

69. David I. Bernstein, Vicki E.Smith, James R. Sherwood, et al (1998). Safety and immunogenicity of live attenuated human rotavirus vaccine pp.89-12.

70. De Mol p, Zissis G, Butzler JP, et al (1986), “Failure of live, attenuated oral rotavirus vaccine”, Lancet, 2(8498), pp. 108.

71. De Vos B. (2005), "Phase III evaluation of the GlaxoSmithKline human live attenuated vaccine", Precented at the Sixth International Rotavirus Symposium, Mexico City.

72. Delem A., Lobmann M., Zygraich N. (1984), “A bovine rotavirus developed as a candidate vaccine for use in humans”, J Biol. Stand; 12: pp.443-445.

73. Dennehy PH (2000), “Transmission of Rotavirus and other enteric pathogens in the home”, Pediatr Infect Dis J, 19(10 Suppl), pp. SI 03-5.

74. Dennehy PH, Brady RC, Halperin SA, et al (2005), “Comparative evaluation of safety and immimogenicity of two dosages of an oral live attenuated human rotavirus vaccine”, Pediatr Infect Dis J, 24(6), pp 481-88.

75. Dennehy PH. (2007), "Rotavirus vaccines-an update", Vaccine,

25(16): 3137-41.

76. Doan LT, Okitsu S, et al (2003), “Epidemiological features of rotavirus infection among hospitalized children with gastroenteristis in Ho Chi Minh City, Vietnam”, J. Med Virol, 69(4), pp. 588-94.

77. Esparza J., Gil F. (1978), “A study on the ultrastructure of human Rotavirus”, Virology, (91), pp.141-150.

78. Estes M. Rotaviruses and their replication. In: Knipe DM, Howley, P.M., editor. (2001), "Fields Virology", Philadelphia, Lippincott Williams and Wilkins, 1747-87.

79. Estes MK., Graham DY., Smith EM., et al (1979), "Rotavirus stability and inactivation", J Gen Virol, 43, pp. 403 - 409.

80. Fang ZY, Ye Q, Ho MS, et al (1989), “Investigation of an outbreak of adult diarrhea Rotavirus in China”, J. Infect. Dis, 160(6), pp. 948-53.

81. Flewen, T.H., and Woode, G.N. (1978), "The Rotaviruses". Arch Virology, 57, pp. 1-23.

82. Fu C, Wang M, Liang J, et al (2007), "Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study", Vaccine; 25(52):8756-61.

83. Gentsch JR, Glass RI, Woods P, et al. (1992), "Identification of group A rotavirus gene 4 types by polymerase chain reaction", J Clin Microbiol; 30(6): 1365-73.

84. Gentsch JR, Woods PA, Ramachandran M, et al. (1996), "Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development", J Infect Dis; 174 Suppl 1: S30-7.

85. Georges-Courbot MC, Monges J, Siopathis MR, et al (1991), “Evaluation of the efficacy of a lowpassage bovine rotavirus (strain WC3) vaccine in children in Central Africa”, Res Virol, 142(5), pp. 405-411.

86. Glass RI, Bhan MK, Ray P, et al. (2005), "Development of candidate rotavirus vaccines derived from neonatal strains in India", J Infect Dis; 192 Suppl 1: S30-5.

87. Guillermo M. Ruiz-Palacious, M.D., et al. (2006), “Safety and Effìcacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis”, The Neu England joumal of medicine, January 5, 2006, Vol. 354, No. 1.

88. Gunasena S, Nakagomi O, Isegawa Y, et al. (1993), "Relative frequency of VP4 gene alleles among human rotaviruses recovered over a 10-year period (1982-1991) from Japanese children with diarrhea", J Clin Microbiol; 31(8): 2195-7.

89. Gurwith M, Wenman W, Gurwith D, et al (1983), “Diarrhea among infants and young children in Canada: a longitudinal study in three northem communities”, JInfect Dis, 147(4), pp. 685-692.

90. H. F Clark, P.A Offit, R.W. Ellis, et al 1996), The Journal of Infectious Diseases, The Development of Multivalen Bovine Rotavirus (Strain WC3) Reassortant Vaccine for Infants, pp 73-80.

91. Holland RE (1990), "Some infectious causes of diarrhea in young farm animals", Clin Microbiol Rev, 3(4), pp. 345-75.

92. Hopkins RS, Gaspard GB, Williams FP, et al (1984). "A community waterbome gastroenteritis outbreak: evidence for rotavirus as the agent", Am J Public Health, 74(3), pp. 263-5.

93. Ismail E Haffejee (1995), "The epidemiology of Rotavirus infection", A global perspective Joumal pediatric gastroenterology and nutrition, Vol 20, pp. 275 -281.

94. Jennison C, Tumbull BW (2000), Group sequential methods with applications to clinical trials, Chapman and Hall/CRC, Boca Raton, USA.

95. Jiang B, Gentsch JR, Glass RI. (2008), "Inactivated rotavirus vaccines: a priority for accelerated vaccine development", Vaccine; 26(52):6754-8.

96. Jiang B, Wang Y, Saluzzo JF, Bargeron K, et al (2008), "Immunogenicity of a thermally inactivated rotavirus vaccine in mice", Hum Vaccin; 4(2):143-7.

97. Jimena p. V., Pavel I., Susana L., Carlos F.A. (2006), "Rotavirus vaccine: Early Introdution in Latin America-Risks and Benefits", Archives of Medical Research, 37: 1-10.

98. Joensuu J, Koskenniemi E, Pang XL, et al (1997), “Randomised, doubleblind, placebo controlled trial of rhesus-human reassortant Rotavirus vaccine for prevention of severe Rotavirus gastroenteritis”, Lancet, 350(9086), pp. 1205-1209.

99. Joseph Bresee, Zhao-Yin Fang, Bei Wang, et al (2004), "First Report from the Asian Rotavirus Surveillance network", Emerging Infectiuos Diseases Vol 10, No 6, P: 988-995.

100. Kapikian A.Z., Yolken R.H., Greenberg H.B., et al (1980), Gastroenteritis viruses. In Diagnostic Procedures for viral, Rickettsial and Chlamydial Infections. 5th Ed, Pub Health Assoc, Washington, D.C., pp. 927 - 996.

101. Kapikian AZ. Rotaviruses. In: knipe DM, Howley, P.M., editor. (2001), "Fields Virology", Philadelphia, Lippincott, Williams and Wilkins.

102. Kong Boo Phua, Seng Hock Quak, et al.(2005), "Evaluation of R1X4414, A live, Attenuated Rotavirus Vaccine, in a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial Involving 2464 Singaporean Infants", JID 2005:192 (suppl 1) S6-16.

103. Kurtz. JB., Lee TW., Parsons AJ. (1980), "The action of alcohols on Rotavirus, astrovirus and enterovirus", J Hosp Infect, 1, pp. 321 - 325.

104. Levy K, Hubbard AE, Eisenberg JN (2009), “Seasonality of rotavirus disease in the tropics: a systematic review and meta-analysis”, Int J Epidemiol, 38(6), pp. 1487-96.

105. Lias MM. (1979), "Distribution and titres of Rotavirus antibodies in different age groups", J Hy, 79, pp. 365 - 372.

106. Linhares AC, Bresee JS (2000), “Rotavirus vaccines and vaccination in Latin America”, Rev Panam Salud Pubiica, 8(5), pp. 305-31.

107. Linhares AC, Carmo KB, Oliveira KK, et al (2002), “Nutritional status in relation to the efficacy of the rhesus-human reassortant, tetravalent rotavirus vaccine (RRV-TV) in infants from Belém, pará State, Brazil”, Rev Inst Med Trop Sao Paulo, 44(1), pp. 13-6.